Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03644667 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab in Cardiac Transplantation
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT03644667 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 385 participants.
The verdict
NCT03644667, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant. Specifically, the investigators will evaluate whether taking tocilizumab leads to less rejection, less development of unwanted antibodies, and better heart function.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL tocilizumab
- DRUG Standard of Care Triple IS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2025-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03644667
The ClinicalTrials.gov registry entry for NCT03644667 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03644667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03644667 about?
NCT03644667 is a clinical study titled "Tocilizumab in Cardiac Transplantation". The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant. Specifically, the investigators will evaluate whether taking tocilizumab leads to les...
What is the current status of trial NCT03644667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2018-12-20. Estimated completion is 2025-03-25.
What interventions are being tested in trial NCT03644667?
The interventions under investigation include: Placebo (BIOLOGICAL), tocilizumab (BIOLOGICAL), Standard of Care Triple IS (DRUG).
Who is sponsoring clinical trial NCT03644667?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.